These cookies can be session-level or persistent, and they will be stored on your computer even after you close your browser. Syneos Health's acquisition of StudyKIK expands its technology-enabled clinical trial CRO’s recruitment capabilities. Its recent acquisitions also include Illingworth Research Group, Ride Health, Science37, and Medable.
These partnerships are intended to enhance Syneos Health's offerings and extend its reach in the biopharmaceutical industry. The acquisition of StudyKIK also complements Syneos Health's portfolio and capabilities.
Syneos Health is a fully integrated biopharmaceutical solutions organization with a global footprint. Its three segments -
CRO’s and Contract Commercial Organization (CCO) - deliver diverse solutions and services to help clients improve their performance.
The CCO segment offers consulting services to clients and a range of fit-for-purpose solutions ranging from Phase I to Phase IV. The CRO’s sector includes biostatistics programming, data management, clinical staffing, and quality risk management services.
With a fully integrated biopharmaceutical solutions organization, Syneos Health integrates its CRO and CCO disciplines to accelerate the development and commercialization of biopharmaceutical therapies. For instance, it offers a Patient Voice Consortium, a cross-functional hub that integrates clinical, commercial, and regulatory capabilities. Its unique platform also includes a behavioral science and health policy expertise.
In order to provide more innovative services, Syneos Health partners with industry-leading technology companies. It has announced a strategic alliance with Science 37, a decentralized clinical trial operating system. This partnership will streamline workflow orchestration, real-world evidence generation, and data harmonization.
commentaires